In a recent study19, genomic losses were also reported to be the major contributor to the first and second quartile CNA burden in men with high risk node negative (M0N0; defined as having at least two of tumour stage category T3/4, prostate-specific antigen (PSA) ≥ 40 ng/ml, or Gleason sum score 8–10) or node positive (M0N1) and metastatic (M1) PCa recruited to the control arm of the STAMPEDE trial (NCT00268476). The gene discussed is KLK3; the disease is neoplasm.